Tetrahedron 66 (2010) 4888-4893

Contents lists available at ScienceDirect

Tetrahedron

journal homepage: www.elsevier.com/locate/tet

Synthesis of 5-(3-indolyl)oxazole natural products. Structure revision of Almazole D

Fumiko Miyake, Michinao Hashimoto, Sorasaree Tonsiengsom, Kenichi Yakushijin, David A. Horne*

Department of Molecular Medicine, Beckman Research Institute at City of Hope, 1500 E. Duarte Road, Duarte, CA 91010, USA

A R T I C L E I N F O

ABSTRACT

Article history: Received 15 February 2010 Received in revised form 28 March 2010 Accepted 29 March 2010 Available online 2 April 2010

Keywords: Oxazole Synthesis Natural products Antibiotics

1. Introduction

Almazole D (1) is a secondary metabolite isolated from red alga that possesses potent antibacterial activity against Gram-negative bacteria such as *Serratia marcescens* and *Salmonella typhi* LXD.¹ These and related pathogenic bacteria are of high concern due to the increasing number of infectious cases, virulence, and resistance to antibiotics. The structure elucidation of 1 has been reported by Pietra and co-workers in which chemical modification studies involving the treatment of 1 with diazomethane yielded methylated analog 2. Comparison of NMR data obtained for 1 and 2 with those for almazole C (3)² led to the proposed structure 1 for almazole D. In this report, we describe the results of our synthetic efforts in this area for which a structure revision of almazole D is proposed.

2. Results and discussion

One piece of data that remained at odds with proposed structure **1** is the ¹³C chemical shift value of the indole C3. The reported value for C3 of **1** and **2** are 105.05 (s) and 103.90 (s) ppm, respectively. Upon examining related indole derivatives reported in the literature as well as those synthesized by our laboratory,³ these values are more consistent with 5-(3-indolyl)oxazole structures that lack a carbonyl substituent at C3 and better correspond to almazole C (**3**)



The synthesis and utility of β -oxotryptamine and β -oxytryptophan ester synthons provide a convenient

entry to 5-(3-indolyl)oxazole natural products leading to a structure revision of almazole D.



almazole C (3)

© 2010 Published by Elsevier Ltd.

almazole D (1) R=H (C3 δ=105.1) 2 R=CH3 (C3 d=103.9)





prealmazole C (5)

and martefragin A (**4**).⁴ Indoles based on an oxotryptamine motif such as prealmazole C (**5**)² typically have C3 chemical shift values in the range of 113–116 ppm. This holds true for a number of oxotryptamine derivatives that we have investigated, particularly those found in the bisindole alkaloid series.³ Additionally, the formation of almazole D (**1**) from a biosynthetic viewpoint involving tryptophan and *N*,*N*-dimethyl-L-phenylalanine would require an unprecedented oxidative deamination event to explain the extra carbonyl group and hydroxyl moiety contained in the oxazole ring. Based on these observations, we concluded that the original structure **1** proposed for almazole D is likely misassigned and that





^{*} Corresponding author. Tel.: +1 626 471 7310; fax: +1 626 930 5410; e-mail address: dhorne@coh.org (D.A. Horne).

^{0040-4020/\$ –} see front matter \odot 2010 Published by Elsevier Ltd. doi:10.1016/j.tet.2010.03.109

the correct structure of the antibiotic is 5-(3-indolyl)oxazole **6**. This new structure is also more reasonable from a biosynthetic view-point as delineated for martefragin A (**4**).⁴



almazole D (6)

Our synthetic studies began with almazole C (3), a related secondary metabolite isolated from red alga. Structure 3 was previously confirmed through synthesis in which a Robinson-Gabriel² cyclization served as the key oxazole forming step. The optical rotation, however, reported for the natural material $[\alpha]_{D}^{23}$ +168 (c 1.08, MeOH) is significantly higher than the synthesized material $[\alpha]_{D}^{23}$ +138 (c 0.1, MeOH).² One possibility to account for this discrepancy is epimerization of the dimethylamino center during cyclization. While the Robinson-Gabriel method is one of the most widely used procedures for the preparation of oxazoles,⁵ cyclodehydrations of chiral α -acylamino ketones having epimerizable centers often pose a problem under these conditions.⁶ Thus, one of the key objectives of this study not only involves the structure confirmation of almazole D but the preparation of two key synthons, oxo-tryptamine (8) and -tryptophan ester (13) and their use in a Robinson-Gabriel approach to chiral, non-racemic oxazole synthesis.

In a previous communication,³ the reduction of indole-3carbonyl nitrile (**7**)⁷ produced oxotryptamine (**8**), which is an important synthon found in many structural motifs of biologically active natural products. This procedure enables the convenient preparation of **8** in large quantities. With **8** in hand, initial studies were directed at examining reaction conditions necessary to effect the Robinson–Gabriel cyclization which is typically performed at elevated temperatures. Acylation of **8** with the corresponding acid chloride produced ketoamides **9a–d**. Treatment of **9a–d** with POCl₃ at room temperature produced excellent yields of streptomyces and/or streptoverticillium metabolites pimprinethine (**10a**),⁸ WS-30581A (**10b**),⁹ WS-30581B (**10c**),⁹ and unnatural analog (**10d**) (Scheme 1).



Next, using optically pure *N*,*N*-dimethyl-L-phenylalanine (**11**), diethylphosphoryl cyanide (DEPC)¹⁰ facilitated acylation with 8 producing prealmazole C (5), $\left[\alpha\right]_{D}^{23}$ +99 (c 0.27, MeOH) (lit.² $\left[\alpha\right]_{D}^{23}$ +38, c 0.25, MeOH) (Scheme 2). It should be noted that a large discrepancy in specific rotation exists between our work and that reported by Pietra and co-workers. Treatment of 5 with POCl₃ at 23 °C for one day did not produce appreciable amounts of almazole C(3): however, heating the reaction to 60 °C for two days produced good yields of **3**, $[\alpha]_D^{23}$ +156 (*c* 0.27, MeOH). At 90 °C, almazole C (**3**) can be obtained in shorter reaction time but the higher temperature afforded **3** in lower optical purity ($[\alpha]_D^{23}$ +91, *c* 0.27, MeOH). The optical purity of **3** resulting from both sets of reaction conditions was also evaluated by NMR analysis in the presence of (R)-Mosher's acid.¹¹ Under 60 °C cyclization conditions, >97% enantiomeric product purity was obtained as indicated by the presence of a single methyl signal seen at δ 2.86 ppm in CDCl₃. At 90 °C, however, epimerization was evident in the product by the presence of two methyl signals at δ 2.86 and 2.84 ppm.



Our attention next turned to the synthesis of oxazole **6**, the revised structure proposed for almazole D. The synthesis required the preparation of oxotryptophan methyl ester **13** (Scheme 3). This was achieved through hydrolysis of oxazole **12**, which is easily obtained from the cycloaddition of methyl isocyanoacetate and acyl nitrile **7**.¹² Acid hydrolysis of **12** produced oxotryptophan **13** (75%) and minor amounts oxotryptamine **8** (5%), which occurred through decarboxylation.



While Vinograd and co-workers¹³ reported the keto–enol tautomeric behavior of oxotryptophan ethyl ester (**13a/13b**) (Eq. 1) (prepared in two steps from ethyl β -keto- β -(3-indolyl)propionate) in pyridine- d_5 and/or MeOH- d_4 , we were unable to observe different tautomeric species in the ¹H NMR spectrum of **13** in a variety of solvents (pyridine- d_5 , CDCl₃, DMSO- d_6 , and MeOH- d_4) as well as in the ¹³C NMR spectrum measured in DMSO- d_6 . The methine hydrogen, however, did undergo rapid deuterium exchange in the presence of D₂O. While it is reported that some α -C-acylamino acid ester hydrochlorides exist predominantly as the enol tautomer observed by ¹H NMR measurements in DMSO- d_6 ,¹² we found the indole analog **13** · HCl resides predominantly in the keto form in both MeOH- d_4 and DMSO- d_6 as evidenced by their ¹H and ¹³C NMR spectra.



DEPC coupling of **13** with *N*,*N*-dimethyl-L-phenylalanine (**11**) produced a 1:1 diastereomeric mixture of amides **14**. Although each diastereomer is initially separable by column chromatography, significant epimerization was observed upon standing in DMSO- d_6 . Treatment of 14 with POCl₃ (60 °C, seven days) afforded oxazole 15 $[\alpha]_{D}^{23}$ +115 (c 0.13, MeOH) and recovered starting material in ~1:1 ratio. Cyclization of **14** was significantly slower than prealmozole C (5) presumably due to greater steric hindrance. Complete disappearance of starting material was observed at higher temperatures (90 °C, two days), however, significant epimerization occurred as evidenced by the presence of two -NMe₂ product signals at δ 2.97 and 2.95 ppm (CDCl₃) in the presence of (R)-Mosher's acid. Direct comparison of ¹H and ¹³C NMR spectra of **15** and methylated almazole D 2 revealed a perfect match, suggesting a structure revision for **2** to **15**. Further evidence for this revision can be found in the hydrolysis of ester 15, which produced carboxylic acid 16 upon acidification with HCl. The neutral (or zwitterionic) form 17 can be obtained through flash chromatography (Scheme 4).



Both the ¹H and ¹³C NMR spectra of **17** (MeOH- d_4) as well as the UV spectrum in the presence of NaOH (1.5 equiv) were identical (Fig. 1) to corresponding spectra obtained for almazole D (**1**) isolated from natural sources.

In summary, we have demonstrated the utility of the Robinson–Gabriel oxazole synthesis with chiral, non-racemic ketoamides. In addition, a convenient preparation of β -oxotryptophan methyl ester has been developed. These investigations have led to a structure revision of the antibiotic, almazole D.

3. Experimental section

3.1. General methods

Unless otherwise noted, materials were obtained from commercial suppliers and used without further purification except for solvents, which were dried and distilled. POCl₃ and acid chlorides were freshly distilled before use. All reactions were carried out under inert atmosphere (N₂) unless otherwise specified. Silica gel (particle size 32–63 μ) was used for flash chromatography.

3.1.1. β-Oxotryptamine (8). A mixture of indolyl-3-carbonyl nitrile (7) (5.0 g, 29 mmol) and 10% Pd/C (1.5 g) in 150 mL of acetic acid was stirred under a balloon of hydrogen. After 16 h, the reaction mixture was filtered over Celite and the filtrate concentrated under reduced pressure. The resulting residue was dissolved in ethanol containing concd HCl (5% by volume). Concentration under vacuo vielded $7 \cdot \text{HCl}$ as a reddish-brown solid (4.6 g, 90%). ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.45 (1H, br s), 8.50 (1H, d, *J*=2.9 Hz), 8.36 (2H, br s), 8.15 (1H, dd), 7.52 (1H, dd), 7.23 (2H, td×2), 4.34 (2H, d, *J*=5.1 Hz), 3.42 (2H, s) ppm. Compound **7** (free base): ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.45 (1H, br s), 8.31 (1H, s), 8.17 (1H, br s), 7.46 (1H, dd), 7.22–7.15 (2H, m), 3.89 (2H, br s) ppm; ¹³C NMR (75 MHz, DMSO-d₆) δ 195.3 (s), 136.5 (s), 133.0 (d), 125.4 (s), 122.7 (d), 121.6 (d), 121.2 (d), 114.3 (s), 112.1 (d), 48.2 (t) ppm; MS m/z (relative intensity)=175 (M⁺+1, 100), 144 (30); HRMS calcd for C₁₀H₁₁N₂O (M⁺+1): 175.0871; found:175.0869.

3.1.2. N-[2-(1H-Indole-3-yl)-2-oxo-ethyl]-alkylamide **9**. General procedure A. To a stirred solution of β -oxotryptamine **3** (0.30 g, 1.7 mmol) in 20 mL of THF and triethylamine (0.18 mL, 2.5 mmol) was added acid chloride (1.9 mmol) dropwise at 23 °C. The reaction mixture was stirred for 30 min and concentrated. The



residual product was dissolved in 100 mL of ethyl acetate, washed with brine (2×50 mL), dried (MgSO₄), and filtered. Concentration of the filtrate under reduced pressure afforded indole-oxo-alkylamide **9**. The product was filtered and washed with methylene chloride.

3.1.3. *N*-[2-(1*H*-Indole-3-yl)-2-oxo-ethyl]-propionamide (**9a**). General procedure A was used to prepare indole-oxo-alkylamide **9a** from propionyl chloride (0.17 g, 1.9 mmol). Upon concentration under vacuum, compound **9a** crystallized as a light yellow solid (0.34 g, 85%); mp 221–223 °C; IR (KBr) 3299, 3188, 1662, 1616, 1439 cm⁻¹; ¹H NMR (300 MHz, DMSO- d_6) δ 11.98 (1H, br s), 8.40 (1H, d, *J*=3.1 Hz), 8.16–8.13 (1H, m), 8.06 (1H, bt, *J*=5.4 Hz) 7.48–7.45 (1H, m), 7.24–7.15 (2H, m), 4.44 (2H, d, *J*=5.6 Hz), 2.18 (2H, q, *J*=7.6 Hz), 1.03 (3H, t, *J*=7.6 Hz) ppm; ¹³C NMR (75 MHz, DMSO- d_6) δ 190.4 (s), 173.2 (s), 136.4 (s), 133.5 (d), 125.4 (s), 122.8 (d), 121.8 (d), 121.1 (d), 114.1 (s), 112.1 (d), 45.6 (t), 28.4 (t), 10.0 (q) ppm; MS *m/z* (relative intensity)=231 (M⁺+1, 100), 175 (10), 154 (10), 144 (25), 114 (20); HRMS calcd for C₁₃H₁₅N₂O₂ (M⁺+1): 231.1134; found: 231.1133.

3.1.4. *N*-[2-(1*H*-Indole-3-yl)-2-oxo-ethyl]-butyramide (**9b**). General procedure A was used to prepare indole-oxo-alkylamide **9b** from butyryl chloride (0.20 g, 1.9 mmol) affording compound **3b** (0.36 g, 87%): ¹H NMR (300 MHz, DMSO- d_6) δ 11.97 (1H, br s), 8.40 (1H, d, *J*=3.1 Hz), 8.16–8.13 (1H, m), 8.08 (1H, br t, *J*=5.7 Hz) 7.48–7.44 (1H, m), 7.24–7.15 (2H, m), 4.44 (2H, d, *J*=5.7 Hz), 2.16 (2H, t, *J*=7.3 Hz), 1.55 (2H, q, *J*=7.3 Hz), 0.89 (3H, t, *J*=7.3 Hz) pm; ¹³C NMR (75 MHz, DMSO- d_6) δ 190.4 (s), 172.3 (s), 136.4 (s), 133.5 (d), 125.4 (s), 122.8 (d), 121.8 (d), 121.1 (d), 114.1 (s), 112.1 (d), 45.6 (t), 37.2 (t), 18.7 (t), 13.6 (q) ppm; MS *m*/*z* (relative intensity)=245 (M⁺+1, 100), 175 (15), 144 (25), 77 (10); HRMS calcd for C₁₄H₁₇N₂O₂ (M⁺+1): 245.1290; found: 245.1286.

3.1.5. Pentanoic acid [2-(1H-indole-3-yl)-2-oxo-ethyl]-amide (**9c**). General procedure A was used to prepare indole-oxo-alkylamide **9c** from valeryl chloride (0.23 g, 1.9 mmol) affording compound **9c** (0.37 g, 84%); mp 207–210 °C; IR (KBr) 3320, 3190, 1653, 1626, 1436 cm⁻¹; ¹H NMR (300 MHz, DMSO- d_6) δ 11.97 (1H, br s), 8.40 (1H, d, *J*=2.9 Hz), 8.16–8.13 (1H, m), 8.08 (1H, br t, *J*=5.3 Hz) 7.47–7.45 (1H, m), 7.23–7.15 (2H, m), 4.43 (2H, d, *J*=5.7 Hz), 2.18 (2H, t, *J*=7.3 Hz), 1.51 (2H, m), 1.29 (2H, m), 0.87 (3H, t) ppm; ¹³C NMR (75 MHz, DMSO- d_6) δ 190.4 (s), 172.4 (s), 136.4 (s), 133.5 (d), 125.4 (s), 122.8 (d), 121.8 (d), 121.1 (d), 114.1 (s), 112.1 (d), 45.6 (t), 35.0 (t), 27.5 (t), 21.8 (t), 13.8 (q) ppm; MS *m*/*z* (relative intensity)=259 (M⁺+1, 100), 175 (20), 159 (5), 144 (30), 136 (10); HRMS calcd for C₁₅H₁₉N₂O₂ (M⁺+1): 259.1446; found: 259.1144.

3.1.6. 3-Methyl-but-2-enoic acid [2-(1H-indole-3-yl)-2-oxo-ethyl]amide (**9d**). General procedure A was used to prepare indole-oxoalkylamide **9d** from 3,3-dimethylacryloyl chloride (0.22 g, 1.9 mmol) affording compound **9c** (0.36 g, 81%); mp 230–233 °C; IR (KBr) 3333, 3220, 1626, 1515, 1435 cm⁻¹; ¹H NMR (300 MHz, DMSO-d₆) δ 11.98(1H, br s), 8.41(1H, d, J=3.0 Hz), 8.16–8.14 (1H, m), 8.03 (1H, br t, J=5.7 Hz) 7.49–7.46 (1H, m), 7.24–7.16 (2H, m), 5.8 (1H, s), 4.47 (2H, d, J=5.8 Hz), 2.08 (3H, s), 1.80 (3H, s) ppm; ¹³C NMR (75 MHz, DMSO-d₆) δ 190.6 (s), 166.2 (s), 148.8 (s), 136.4 (s), 133.5 (d), 125.4 (s), 122.8 (d), 121.8 (d), 121.1 (d), 118.9 (d), 114.1 (s), 112.1 (d), 45.4 (t), 26.8 (q), 19.3 (q) ppm; MS *m/z* (relative intensity)=257 (M⁺+1, 100), 75 (10), 159 (5), 144 (25), 82 (40); HRMS calcd for C₁₅H₁₇N₂O₂ (M⁺+1): 257.1290; found: 257.1283.

3.1.7. 1-Benzyl-3-[2-(1H-indole-3-yl)-2-oxo-ethyl]-1-isopropyl-urea (**5**). To a stirred solution of β -oxotryptamine **3**·HCl (0.50 g, 1.3 mmol) in 100 mL of THF under nitrogen was added triethyl-amine (0.27 mL, 1.95 mmol) at 0 °C. After 30 min, *N*,*N*-dimethyl-L-phenylalanine (0.27 g, 1.4 mmol) and diethyl pyrocarbonate

(0.17 mL, 1.4 mmol) was added and the resulting solution was allowed to warm to 23 °C. After 12 h, the reaction mixture was concentrated under vacuum. The residual product was dissolved in 100 mL ethyl acetate, washed with brine $(2 \times 50 \text{ mL})$, dried (MgSO₄), and filtered. Concentration under vacuum afforded a residue that was purified by flash chromatography (CH₂Cl₂/MeOH 39:1) to give prealmazole C (**5**) (0.38 g, 85% yield) as a solid; mp 141–143 $^{\circ}$ C; ¹H NMR (300 MHz, CDCl₃) δ 9.65 (1H, br s), 8.32–8.29 (1H, m), 7.88 (1H, d, J=3.1 Hz), 7.83 (1H, br t, J=4.5 Hz), 7.42-7.37 (1H, m), 7.32-7.15 (7H, m), 4.63 (1H, dd, *J*=18.2, 5.0 Hz), 4.51 (1H, dd, *J*=18.2, 4.6 Hz), 3.41 (1H, dd, *J*=7.7, 5.8 Hz), 3.22 (1H, dd, *J*=13.8, 7.7 Hz), 3.01 (1H, dd, *J*=13.8, 5.8 Hz), 2.42 (6H, s) ppm. ¹H NMR (300 MHz, DMSO- d_6) δ 11.99 (1H, br s), 8.42 (1H, d, J=2.4 Hz), 8.16–8.10 (2H, m), 7.49–7.46 (1H, m), 7.24–7.13 (7H, m), 4.53 (1H, dd, J=17.4, 5.8 Hz), 4.36 (1H, dd, J=17.4, 5.3 Hz), 3.38 (2H, dd, J=8.1, 5.9 Hz), 2.99 (1H, dd, J=13.6, 8.1 Hz), 2.80 (1H, dd, J=13.6, 5.9 Hz), 2.31 (6H, s) ppm. ¹H NMR (300 MHz, acetone- d_6) δ 11.15 (1H, br s), 8.35 (1H, d, J=3.2 Hz), 8.32-8.26 (1H, m), 7.72 (1H, br s), 7.56-7.50 (1H, m), 7.33-7.11 (7H, m), 4.65 (1H, dd, J=18.0, 5.5 Hz), 4.50 (1H, dd, J=18.0, 4.9 Hz), 3.45 (1H, dd, J=7.6, 5.8 Hz), 3.16 (1H, dd, J=13.7, 7.6 Hz), 2.92 (1H, dd, J=13.7, 5.8 Hz), 2.39 (6H, s) ppm; ¹³C NMR (100.1 MHz, acetone-d₆) δ 190.0 (s), 171.7 (s), 140.9 (s), 137.2 (s), 133.1 (d), 129.7 (d×2), 128.5 (d×2), 126.2 (s), 126.1 (d), 123.5 (d), 122.4 (d), 122.1 (d), 115.2 (s), 112.4 (d), 70.7 (d), 46.1 (t), 41.9 (q×2), 33.3 (t) ppm; MS m/z (relative intensity)=350 (M⁺+1, 40), 307 (5), 258 (10), 148 (100); HRMS calcd for C₂₁H₂₄N₃O₂ (M⁺+1): 350.1868; found: 350.1871.

3.1.8. 3-(2-Alkyl-oxazole-5-yl)-1H-indole (**10**). General procedure B. A mixture of **9** (~0.5 mmol) in 5 mL of POCl₃ was stirred at 23 °C. The reaction was allowed to proceed overnight and concentrated under reduced pressure. The residual product was dissolved in 50 mL of ethyl acetate, washed with saturated aqueous NaHCO₃ (50 mL), brine (2×50 mL), dried (MgSO₄), and filtered. Concentration of the filtrate under reduced pressure gave alkyl oxazole indole **10**. The product was filtered and washed with ether.

3.1.9. 3-(2-Ethyl-oxazole-5-yl)-1H-indole (**10a**). General procedure B was used to prepare alkyl oxazole indole **10a** from **9a** (0.10 g, 0.43 mmol) affording compound **10a** (0.082 g, 90%); mp 161–163 °C; IR (KBr) 3456, 3175, 2368, 2344, 1634 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 8.77 (1H, br s), 7.86–7.83 (1H, bd, J=8.3 Hz), 7.52 (1H, d, J=2.4 Hz), 7.45–7.42 (1H, bd, J=8.6 Hz), 7.31–7.22 (2H, bq), 7.17 (1H, s), 2.89 (2H, q), 1.42 (3H, t); ¹³C NMR (75 MHz, CDCl₃) δ 163.8 (s), 147.3 (s), 136.3 (s), 124.1 (s), 122.9 (d), 121.6 (d), 120.8 (d), 119.9 (d), 119.6 (d), 111.6 (d), 105.9 (s), 21.7 (t), 11.3 (q); MS *m*/*z* (relative intensity)=213 (M⁺+1, 100), 154 (5), 136 (5); HRMS calcd for C₁₃H₁₃N₂O (M⁺+1): 213.1028; 213.1028.

3.1.10. 3-(2-Propyl-oxazol-5-yl)-1H-indole (**10b**). General procedure *B* was used to prepare alkyl oxazole indole **10b** from **9b** (0.10 g, 0.40 mmol) affording compound **10b** (0.08 g, 88% yield); mp 161–163 °C; ¹H NMR (300 MHz, DMSO- d_6) δ 11.52 (1H, br s), 7.82 (1H, br d *J*=7.7 Hz), 7.72 (1H, d, *J*=2.6 Hz), 7.46 (1H, br d, *J*=7.8 Hz), 7.28 (1H, s), 7.19 (1H, br t, *J*=7.7 Hz), 7.13 (1H, br t, *J*=7.7 Hz), 2.76 (2H, t), 1.76 (2H, m), 0.97 (3H, t); ¹³C NMR (75 MHz, DMSO- d_6) δ 161.5 (s), 147.2 (s), 136.3 (s), 123.5 (s), 122.9 (d), 122.1 (d), 120.0 (d), 119.4 (d), 119.0 (d), 112.0 (d), 103.9 (s), 29.3 (t), 20.1 (t), 13.5 (q); MS *m/z* (relative intensity)=227 (M⁺+1, 100), 154 (5), 136 (5); HRMS calcd for C₁₄H₁₅N₂O (M⁺+1): 227.1184; found: 227.1186.

3.1.11. 3-(2-Butyl-oxazol-5-yl)-1H-indole (**10c**). General procedure B was used to prepare alkyl oxazole indole **10c** from **9c** (0.10 g, 0.38 mmol) affording compound **10c** (0.079 g, 86% yield); mp 122–124 °C; IR (KBr) 3456, 3128, 2368, 2344, 1632 cm⁻¹; ¹H NMR

 $\begin{array}{l} (300 \text{ MHz}, \text{DMSO-}d_6) \, \delta \, 11.50 \, (1\text{H}, \text{br s}), 7.80 \, (1\text{H}, \text{br d}, J=7.6 \, \text{Hz}), 7.70 \\ (1\text{H}, d, J=2.6 \, \text{Hz}), 7.44 \, (1\text{H}, \text{br d}, J=7.8 \, \text{Hz}), 7.26 \, (1\text{H}, \text{s}), 7.18 \, (1\text{H}, \text{br t}, J=7.6 \, \text{Hz}), 7.11 \, (1\text{H}, \text{br t}, J=7.6 \, \text{Hz}), 2.78 \, (2\text{H}, \text{t}), 1.72 \, (2\text{H}, \text{m}), 1.38 \\ (2\text{H}, \text{m}), 0.91 \, (3\text{H}, \text{t}); {}^{13}\text{C} \, \text{NMR} \, (75 \, \text{MHz}, \text{DMSO-}d_6) \, \delta \, 161.6 \, (\text{s}), 147.2 \\ (\text{s}), 136.3 \, (\text{s}), 123.5 \, (\text{s}), 122.9 \, (\text{d}), 122.0 \, (\text{d}), 120.0 \, (\text{d}), 119.4 \, (\text{d}), 119.0 \\ (\text{d}), 112.0 \, (\text{d}), 103.9 \, (\text{s}), 28.7 \, (\text{t}), 27.0 \, (\text{t}), 21.6 \, (\text{t}), 13.6 \, (\text{q}); \, \text{MS} \, m/z \\ (\text{relative intensity})=241 \, (\text{M}^++1, 100), 211 \, (5), 144 \, (5), 136 \, (5), 107 \\ (5); \, \text{HRMS calcd for } C_{15}\text{H}_{17}\text{N}_2\text{O} \, (\text{M}^++1): 241.1341; \, \text{found: } 241.1340. \\ \end{array}$

3.1.12. 3-[(2-Methyl-propenyl)-oxazol-5-yl]-1H-indole(10d). General procedure B was used to prepare alkyl oxazole indole 10d from 9d (0.10 g, 0.39 mmol) affording compound 10d (0.081 g, 87% yield); mp 128–131 °C; IR (KBr) 3166, 2368, 2344, 1631 cm⁻¹; ¹H NMR (300 MHz, DMSO-d₆) δ 11.56 (1H, br s), 7.84 (1H, br d, J=7.8 Hz), 7.74 (1H, d, J=2.8 Hz), 7.45 (1H, br d, J=8.2 Hz), 7.43 (1H, s), 7.18 (1H, br t, J=7.8 Hz), 7.12 (1H, br t, J=7.8 Hz), 6.19 (1H, s), 2.23 (3H, s), 1.96 (3H, s); ¹³C NMR (75 MHz, DMSO-d₆) δ 158.3 (s), 146.2 (s), 144.1 (s), 136.4 (s), 123.5 (s), 123.2 (d), 122.1 (d), 120.2 (d), 120.1 (d), 119.4 (d), 112.1 (d), 111.3 (d), 103.8 (s), 26.7 (q), 20.3 (q); MS *m/z* (relative intensity)=238(M⁺+1, 100), 209 (3), 182 (3), 168 (3), 144 (5), 136 (3); HRMS calcd for C₁₅H₁₅N₂O (M⁺+1): 239.1184; found: 239.1182.

3.1.13. {1-[5-(1H-Indol-3-yl)-oxazol-2-phenyl-ethyl}-dimethylamine (10e). A mixture of 9e (0.10 g, 0.29 mmol) in 5 mL of POCl₃ was stirred at 80 °C for 2 h. Concentration under vacuo afforded a residue that was dissolved in 50 mL of ethyl acetate, washed with saturated aqueous NaHCO₃ (50 mL), brine (3×50 mL), dried $(MgSO_4)$, and filtered. Upon concentration of the filtrate under reduced pressure, **10e** crystallized from the solution. The product was collected by filtration and washed with hexane and ether to give **9e** (0.048 g, 50% yield); mp 115–117 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.48 (1H, br s), 7.84–7.81 (1H, br d, J=7.3 Hz), 7.52 (1H, d, J=2.6 Hz), 7.45-7.43 (1H, br d, J=5.7 Hz), 7.21 (1H, s), 7.32-7.14 (7H, m), 4.09 (1H, dd, *J*=9.6, 5.5 Hz), 3.42 (1H, dd, *J*=13.5, 9.6 Hz), 3.24 (1H, dd, J=13.5, 5.5 Hz), 2.43 (6H, s). ¹H NMR (400 MHz, CDCl₃) δ 8.68 (1H, br s), 7.85 (1H, br d, J=7.5 Hz), 7.54 (1H, d, J=2.4 Hz), 7.46 (1H, br d, J=7.7 Hz), 7.24 (1H, s), 7.34–7.17 (7H, m), 4.13 (1H, dd, *J*=9.7, 5.3 Hz), 3.45 (1H, dd, *J*=13.5, 9.7 Hz), 3.28 (1H, dd, *J*=13.5, 5.3 Hz), 2.47 (6H, s). ¹H NMR (300 MHz, acetone-*d*₆) δ 10.67 (1H, br s), 7.90–7.88 (1H, br d, J=7.2 Hz), 7.74 (1H, d, J=2.6 Hz), 7.52–7.49 (1H, br d, J=5.8 Hz), 7.26 (1H, s), 7.29–7.10 (7H, m), 4.08 (1H, dd, J=9.2, 6.1 Hz), 3.38 (1H, dd, J=13.6, 9.1 Hz), 3.20 (1H, dd, J=13.6, 6.1 Hz), 2.36 (6H, s); ¹³C NMR (75 MHz, acetone- d_6) δ 160.4 (s), 148.4 (s), 139.6 (s), 137.2 (s), 129.6 (d×2), 128.5 (d×2), 126.4 (d), 124.6 (s), 123.2 (d), 122.8 (d), 120.7 (d), 112.3 (d), 105.4 (s), 64.6 (d), 41.5 (q×2), 37.0 (t); MS *m*/*z* (relative intensity)=332 (M⁺+1, 55), 287 (100), 240 (30), 136 (45), 107 (15); HRMS calcd for $C_{21}H_{22}N_3O$ (M⁺+1): 332.1763; found: 332.1766.

3.1.14. Almazole C (**3**). A mixture of **5** (0.1 g, 0.29 mmol) in 5 mL of POCl₃ was stirred at 60 °C for two days. Concentration under reduced pressure afforded a residue that was dissolved in 50 mL of ethyl acetate, washed with saturated aqueous NaHCO₃ (50 mL), brine (3×50 mL), dried (MgSO₄), and filtered. Upon concentration of the filtrate under reduced pressure, **3** crystallized from the solution. The product was filtrated and washed with hexane and ether to give **3** in 0.045 g, 50% yield: mp 115–117 °C; ¹H NMR (300 MHz, acetone-*d*₆) δ 10.67 (1H, br s), 7.90–7.88 (1H, br d, *J*=7.2 Hz), 7.74 (1H, d, *J*=2.6 Hz), 7.52–7.49 (1H, br d, *J*=5.8 Hz), 7.26 (1H, s), 7.29–7.10 (7H, m), 4.08 (1H, dd, *J*=9.2, 6.1 Hz), 3.38 (1H, dd, *J*=13.6, 9.1 Hz), 3.20 (1H, dd, *J*=13.6, 6.1 Hz), 2.36 (6H, s); ¹³C NMR (75 MHz, acetone-*d*₆) δ 160.4 (s), 148.4 (s), 139.6 (s), 137.2 (s), 129.6 (d×2), 128.5 (d×2), 126.4 (d), 124.6 (s), 123.2 (d), 122.8 (d), 120.7 (d), 112.3 (d), 105.4 (s), 64.6 (d), 41.5 (q×2), 37.0 (t); MS *m/z*

(relative intensity)=332 (M^+ +1, 55), 287 (100), 240 (30), 136 (45), 107 (15); HRMS calcd for $C_{21}H_{22}N_3O$ (M^+ +1): 332.1763; found: 332.1761.

3.1.15. Methyl 5-(3-indolyl) oxazole-4-carboxylate (12). To a stirred solution of 7 (1.0 g, 5.9 mmol) in 50 mL of THF at 0 °C was dropwise added α -isocyanoacetate (0.65 mL, 7.1 mmol) and DBU (1.1 mL, 7.1 mmol). The mixture was stirred at room temperature for 10 h. and concentrated. The resulting residue was dissolved in 50 mL ethyl acetate, washed with water (3×30 mL), brine (50 mL), and dried (MgSO)₄. Filtration and evaporation afforded a residue, which was chromatographed over silica gel, eluted with hexane/ethyl acetate 3:2 to give **12** in 1.0 g, 70% yield. Mp 140–142 °C; lR (KBr) 3300, 1699, 1571, 1416 cm⁻¹; ¹H NMR (300 MHz, DMSO- d_6) δ 11.96 (1H, br s), 8.66 (1H, d, J=3.0 Hz), 8.45 (1H, s), 8.05 (1H, br d, J=7.4 Hz), 7.53 (1H, br d, J=7.2 Hz), 7.24 (1H, td, J=7.3, 1.8 Hz), 7.19 (1H, td, J=7.3, 1.8 Hz), 3.84 (3H, s); ¹³C NMR (100.1 MHz, DMSO-d₆) δ 163.5 (s), 154.9 (s), 149.6 (d), 136.9 (s), 130.9 (d), 125.6 (s), 122.6 (s), 123.5 (d), 121.3 (d), 121.9 (d), 113.3 (d), 103.0 (s), 52.4 (q); MS m/z (relative intensity)=242 (M⁺+1, 100), 211 (60), 154 (45), 136 (33); HRMS calcd for C₁₃H₁₂N₂O₃ (M⁺+1): 244.0848; found: 244.0845.

3.1.16. β -Oxotryptophan methyl ester (13). Methyl 5-(3-indolyl) oxazole-4-carboxylate 12 (0.8 g, 3.3 mmol) was dissolved in the mixture of methanol (30 mL) and hydrochloric acid (3 mL). The mixture was stirred at 60 °C for three days and concentrated. Methanol was removed by evaporation and the reaction mixture was purified by flash chromatography using a 19:1-9:1 gradient of $CH_2Cl_2/MeOH (NH_3)$ as the eluent to β -oxotryptophan methyl ester (0.58 g, 2.51 mmol, 76%) as a brown solid. Compound **13 free base**; IR (KBr) 3342, 3277, 1736, 1651, 1618, 1521 cm⁻¹; ¹H NMR (300 MHz, DMSO-d₆) δ 12.14 (1H, br s), 8.47 (1H, s), 8.17-8.11 (1H, m), 7.51-7.48 (1H, m), 7.26-7.18 (2H, m), 5.03 (1H, s), 3.59 (3H, s), 3.36 (1H, q), 2.38 (2H, br s), 1.08 (1H, t); ¹³C NMR (100.1 MHz, DMSO-*d*₆) δ 190.7 (s), 172.7 (s), 137.5 (s), 136.7 (d), 126.5 (s), 124.1 (d), 123.0 (d), 122.1 (d), 115.1 (s), 113.2 (d), 61.3 (d), 53.4 (q). Compound **13** ·**HCl salt**; mp 165–170 °C; ¹H NMR (300 MHz, DMSO- d_6) δ 12.75 (1H, d, J=2.6 Hz), 9.03 (2H, s), 8.74 (1H, d, J=3.3 Hz), 8.15-8.12 (1H, m), 7.57-7.54 (1H, m), 7.31-7.23 (2H, m), 3.71 (3H, s), 3.36 (1H, q), 1.08 (1H, t); 13 C NMR (100.1 MHz, DMSO- d_6) δ 182.5 (s), 166.5 (s), 139.1 (d), 137.7 (s), 126.3 (s), 124.6 (d), 123.7 (d), 121.9 (d), 114.5 (s), 113.7 (d), 57.9 (d), 54.5 (q); HRMS calcd for C₁₃H₁₃N₂O₃ (M⁺+1): 233.0926; found: 233.0922.

3.1.17. N-(N,N-Dimethyl- ι -phenylalanyl)- β -oxotryptophan methyl ester (14). To a stirred solution of β -oxotryptamine 8·HCl (1.0 g, 4.27 mmol) in 100 mL of THF was added triethylamine (1.79 mL, 12.28 mmol) at 0 °C, and the solution was stirred for 30 min. To the mixture was then added diethyl pyrocarbonate (0.69 mL, 4.69 mmol), the mixture was stirred for 30 min. To the mixture was added N,N-dimethyl-L-phenylalanine (0.90 g, 4.70 mmol) and stirred at 23 °C under nitrogen. After 12 h, the reaction was concentrated under vacuum. The residual product was dissolved in 100 mL ethyl acetate, and washed with brine (2×50 mL), and dried (MgSO₄). Filtration and evaporation afforded a residue, which was chromatographed over silica gel, eluted with DCM/MeOH 49:1 to give 14 in 1.05 g, 60% yield: compound 14 Down; IR (KBr) 3366, 3250, 1751, 1654, 1647, 1498 cm⁻¹. ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.15 (1H, br s), 8.69–8.66 (1H, br d, J=7.7 Hz), 8.26 (1H, d, J=1.8 Hz), 8.11-8.08 (1H, br d, J=7.7 Hz), 7.52-7.49 (1H, br d, J=7.7 Hz), 7.27-7.01 (6H, m), 5.90 (1H, d, J=7.7 Hz), 3.64 (3H, s), 3.51 (1H, dd, J=8.6, 5.6 Hz), 2.95 (1H, dd, J=13.4, 8.6 Hz), 2.74 (1H, dd, J=13.2, 5.6 Hz), 2.30 (3H, s); ¹³C NMR (100.1 MHz, DMSO- d_6) δ 186.4 (s), 171.2 (s), 169.4 (s), 140.1 (s), 137.6 (s), 137.1 (d), 129.9 (d), 128.8 (d), 126.6 (d), 126.4 (d), 124.3 (d), 123.2 (d), 122.0 (d), 114.6 (s), 113.3 (d), 68.5 (d), 59.2 (d), 53.2 (q), 42.2 (q), 34.7 (t). Compound **14 Up**; ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.22 (1H, br s), 8.68–8.65 (1H, br d, *J*=7.7 Hz), 8.48 (1H, d, *J*=2.7 Hz), 8.14–8.11 (1H, br d, *J*=7.7 Hz), 7.52–7.49 (1H, br d, *J*=7.7 Hz), 7.27–7.01 (6H, m), 5.97 (1H, d, *J*=13.4, 8.6 Hz), 2.78 (1H, dd, *J*=13.2, 5.6 Hz), 2.20 (3H, s); ¹³C NMR (100.1 MHz, DMSO-*d*₆) δ 186.6 (s), 171.4 (s), 169.2 (s), 140.1 (s), 137.6 (s), 137.2 (d), 129.9 (d), 128.9 (d), 126.7 (d), 126.4 (d), 124.3 (d), 123.2 (d), 122.0 (d), 114.6 (s), 113.3 (d), 68.5 (d), 59.2 (d), 53.3 (q), 42.3 (q), 34.7 (t); MS *m/z* (relative intensity)=408 (M⁺+1, 58), 316 (20), 154 (75), 148 (100); HRMS calcd for C₂₃H₂₆N₃O₄ (M⁺+1): 408.1923; found: 408.1921.

3.1.18. Almazole D methyl ester; methyl 2-[1-(dimethylamino)-2phenylethyl]-5-(3-indolyl)oxazole-4-carboxylate (15). A mixture of 14 (0.4 g, 0.98 mmol) in 5 mL of POCl₃ was stirred at 60 °C. The mixture was stirred for seven days, and concentrated. The residual product was dissolved in 50 mL of ethyl acetate, washed with saturated aqueous NaHCO₃ (3×50 mL) and washed with brine (2×50 mL), and dried (MgSO₄). Filtration and evaporation afforded a residue, which was chromatographed over silica gel, eluted with DCM/MeOH 49:1 to give 15 as colorless solid in 0.19 g, 50% yield and recovered starting material: compound 15 mp 135-139 °C, $[\alpha]_D^{23}$ +115 (*c* 0.105, MeOH). UV λ_{max} (MeOH) 203, 218, 254, 272, 331 nm. IR (KBr) 3333, 2380, 2345, 1690, 1588, 1568, 1458 cm⁻¹; ¹H NMR (300 MHz, CD₃OD-d₆) δ 8.71 (1H, s), 8.15-8.11 (1H, m), 7.51-7.48 (1H, m), 7.29-7.20 (2H, m), 7.20-7.10 (5H, m), 4.87 (3H, s), 4.13 (1H, dd, *J*=10.7, 5.1 Hz), 3.90 (2H, s), 3.46 (1H, dd, *J*=13.3, 10.7), 3.30 $(3H, dd, I=13.3, 5.1 Hz), 2.46 (3H, s); {}^{13}C NMR (75 MHz, CD_3OD-d_6)$ δ 163.2 (s), 158.5 (s), 155.7 (s), 137.8 (s), 136.8 (s), 130.4 (d), 129.0 (d×2), 128.5 (d×2), 126.7 (d), 125.4 (s), 122.9 (d), 121.8 (s), 121.4 (d), 120.7 (d), 112.1 (d), 102.9 (s), 65.0 (d), 51.2 (q), 41.4 (q×2), 37.0 (t); MS m/z (relative intensity)=390 (M⁺+1, 23), 345 (77), 298 (100), 154 (50), 148 (49); HRMS calcd for C₂₃H₂₅N₃O₃ (M⁺+1): 391.1897; found: 391.1898.

3.1.19. Almazole D; 2-[1-(N,N-dimethyl)-2-phenylethyl]-5-(3-in-dolyl)oxazole-4-carboxylic acid (**16**). To the mixture of methanol (15 mL) and 3 N aqueous KOH solution (2 mL) was added**15**(0.1 g, 0.26 mmol) at room temperature for 10 h. The pH of resulting mixture was adjusted to 4 by addition of concd HCl and white precipitates**16**were formed. The precipitation was filtered and washed with water. Almazole D**16·HCl**was converted to free base**17**by flash chromatography (DCM/MeOH–NH₃ 4:6) in 0.09 g, 90% yield. The addition of 1 N of NaOH solution to free base**17**provided almazole D**6**in 85 mg, 85% yield.

3.1.20. Almazole D; 2-[1-(N,N-dimethyl)-2-phenylethyl]-5-(3-indolyl)oxazole-4-carboxylic acid (**16**)-HCl salt. ¹H NMR (300 MHz, CD₃OD-d₆) δ 8.71 (1H, s), 7.86 (1H, br d, J=7.4 Hz), 7.46 (1H, br d, J=7.4 Hz), 7.30-7.15 (7H, m), 5.18 (1H, t, J=8.1 Hz), 4.88 (3H, s), 3.64 (1H, d, J=8.2 Hz), 3.13 (3H, s) ppm; ¹³C NMR (75 MHz, CD₃OD-d₆) δ 163.8 (s), 156.9 (s), 151.9 (s), 136.8 (s), 134.1 (s), 131.3 (d), 129.3 (d×2), 129.1 (d×2), 127.9 (d), 125.2 (s), 123.6 (s), 123.1 (d), 121.5 (d), 120.7 (d), 112.1 (d), 102.4 (s), 64.0 (d), 40.8 (q×2), 35.0 (t); compound **17 free base**: UV λ_{max} (MeOH) 212, 271, 330 nm. IR (KBr) 3421, 2362, 2342, 1618, 1597 cm⁻¹; ¹H NMR (300 MHz, CD₃OD-d₆) δ 8.71 (1H, s), 8.07-8.05 (1H, m), 7.47-7.44 (1H, m), 7.24-7.09 (7H, m), 4.26 (1H, dd, J=10.8, 4.8 Hz), 3.48 (1H, dd, J=13.0, 10.8 Hz), 2.54 (3H, s) ppm; ¹³C NMR (75 MHz, CD₃OD-*d*₆) δ 167.2 (s), 156.8 (s), 153.3 (s), 137.6 (s), 136.7 (s), 129.8 (d), 129.2 (d×2), 128.6 (d×2), 126.8 (d), 125.6 (s), 122.5 (s), 120.9 (d), 120.7 (d), 111.9 (s), 103.6 (s), 65.0 (d), 41.3 (q×2), 36.9 (t); MS *m/z* (relative intensity)=391 (M⁺+1, 12), 376 (90), 331 (100), 307 (70), 284 (35), 219 (18), 148 (40); HRMS calcd for C₂₂H₂₂N₃O₃ (M⁺+1): 376.1662; found: 376.1661.

3.1.21. Almazole D, 2-[1-(dimethylamino)-2-phenylethyl]-5-(3-indolyl)oxazole-4-carboxylic acid sodium salt (**6**). $[\alpha]_D^{23}$ +31, UV λ_{max} (MeOH) 208, 278, 310 nm. ¹H NMR (400 MHz, CD₃OD-d₆, NaOH in D₂O) δ 8.71 (1H, s), 8.06 (1H, br s, *J*=7.4 Hz), 7.47 (1H, br d, *J*=7.4 Hz), 7.24–7.09 (7H, m), 4.08 (1H, dd, *J*=10.8, 4.7 Hz), 3.48 (1H, dd, *J*=13.1, 11.0 Hz), 3.31 (1H, dd, *J*=13.1, 4.7 Hz); ¹³C NMR (100.1 MHz, CD₃OD-d₆, NaOH in D₂O) δ 169.5 (s), 157.4 (s), 151.2 (s), 138.0 (s), 136.7 (s), 129.19 (s), 129.15 (d×2), 129.09 (d), 128.5 (d×2), 126.7 (d), 125.7 (s), 122.2 (d), 120.9 (d), 120.7 (d), 120.5 (d), 111.8 (d), 104.1 (s), 65.3 (d), 41.6 (q×2), 37.3 (t).

Acknowledgements

Financial support from Chugai Pharmaceutical Co. is gratefully acknowledged. The authors thank Professor Graziano Guella providing authentic spectra of natural almazole D for spectral comparison.

Supplementary data

Supplementary data associated with this article can be found in online version at doi:10.1016/j.tet.2010.03.109.

References and notes

- 1. N'Diaye, I.; Guella, G.; Mancini, I.; Pietra, F. Tetrahedron Lett. **1996**, 37, 3049–3050.
- 2. Guella, G.; Mancini, I.; N'Diaye, I.; Pietra, F. *Helv. Chim. Acta* **1994**, 77, 1999–2006.
- (a) Takahashi, S.; Matsunaga, T.; Hasegawa, C.; Saito, H.; Fujita, D.; Kiuchi, F.; Tsuda, Y. Chem. Pharm. Bull. 1998, 46, 1527–1529; (b) Nishida, A.; Fuwa, M.; Fujikawa, Y.; Nakahata, E.; Furuno, A.; Nakagawa, M. Tetrahedron Lett. 1998, 39, 5983–5986; (c) Nishida, A.; Fuwa, M.; Naruto, S.; Sugano, Y.; Saito, H.; Nakagawa, M. Tetrahedron Lett. 2000, 41, 4791–4794.
- 4. Miyake, F. Y.; Yakushijin, K.; Horne, D. A. Org. Lett. 2000, 2, 2121–2123.
- 5. Boyd, G. V. Sci. Synth. 2002, 11, 383-479.
- A mild cyclodehydration procedure of α-acylamino ketones with epimerizable centers has been reported using Ph₃P and l₂. Wipf, P.; Miller, C. P. J. Org. Chem. 1993, 58, 3604–3606.
- 7. Hogan, I. T.; Sainsbury, M. Tetrahedron **1984**, 40, 681–682.
- (a) Noltemeyer, M.; Sheldrick, G. M.; Hoppe, H.-U.; Zeeck, A. J. Antibiot. 1982, 35, 549–555;
 (b) Koyama, Y.; Yokose, K.; Dolby, L. J. Agric. Biol. Chem. 1981, 45, 1285–1287;
 (c) Yoshioka, T.; Mohri, K.; Oikawa, Y.; Yonemitsu, O. J. Chem. Res., Miniprint 1981, 2252–2281;
 (d) Doyle, K.; Moody, C. J. Synthesis 1994, 1021–1022.
- (a) Umehara, K.; Yoshida, K.; Okamoto, M.; Iwami, M.; Tanaka, H.; Kohsaka, M.; Imanaka, H. J. Antibiot. **1984**, 37, 1153–1160; (b) Structure revision of APHEs: Kelly, T. R.; Fu, Y.; Xie, R. L. *Tetrahedron Lett.* **1999**, 40, 1857–1860.
- 10. Yamada, S.; Kasai, Y.; Shioiri, T. Tetrahedron Lett. 1973, 1595-1598
- (a) Baxter, C. A. R.; Richards, H. C. Tetrahedron Lett. 1972, 3357–3358; (b) Belvisi, L.; Gennari, C.; Poli, G.; Scolastico, C.; Salom, B. Tetrahedron: Asymmetry 1993, 4, 273–280; (c) Pellegrini, C.; Strassler, C.; Weber, M.; Borschberg, H.-J. Tetrahedron: Asymmetry 1994, 5, 1979–1992.
- Suzuki, M.; Iwasaki, T.; Miyoshi, M.; Okumura, K.; Matsumoto, K. J. Org. Chem. 1973, 38, 3571–3575.
- Vinograd, L. K.; Sorokina, P.; Turchin, K. F.; Dubinskii, R. A.; Suvorov, N. N. Zh. Org. Khim. 1980, 16, 2222–2226.